ANGN News and Press, Angion Biomedica Corp. From 07/30/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Nikolay Pandev/E+ via Getty Images A couple of household names anchored the earnings releases on Wednesday morning. Home products retailer Bed Bath & Beyond (BBBY) and packaged foods maker General Mills (GIS) announced their quarterly results. AMMO, Inc. (POWW) also issued its financial f...

UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today anno...

Angion Biomedica (ANGN): Q1 GAAP EPS of -$1.56.Revenue of $0.37M (-57.5% Y/Y) misses by $1.52M.Press Release For further details see: Angion Biomedica misses on revenue

UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provid...

Angion Biomedica (ANGN) and Vifor Pharma have completed enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).This indication is part of the ANG-3777 license agreement both parties signed in...

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated a...

Angion is a recent IPO. It has an ongoing phase 3 trial with near-term data readout. Cash balance is a little low. For further details see: Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication

Angion is pioneering a new approach to treating acute organ injuries with a pipeline of assets led by ANG-3777, a hepatocyte growth factor (HGF) mimetic. The company has a pivotal trial ongoing aimed at reducing the severity of Delayed Graft Function after kidney transplant. There...

Angion Biomedica (ANGN): Q4 GAAP EPS of -$1.90 misses by $0.60.Revenue of $0.46M (-34.3% Y/Y) misses by $1.44M.As of December 31, 2020, Angion had cash and cash equivalents totaling $34.6 million.Press Release For further details see: Angion Biomedica EPS misses by $0.60, misses on reve...